Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.59 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14124937 | 0.93 | DDB1 (0.56) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL4962412 | 0.93 | DDB1 (0.56) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL3616336 | 0.92 | DDB1 (0.52) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL7383260 | 0.91 | DDB1 (0.55) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL1966881 | 0.89 | KMT2A (0.52) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL13311996 | 0.89 | DDB1 (0.56) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL3497895 | 0.87 | DDB1 (0.55) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL3625138 | 0.86 | DDB1 (0.50) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL28404362 | 0.86 | DDB1 (0.50) | DDB1CRBNALDH1A1 | |
| SCHEMBL6823839 | 0.85 | MEN1 (0.59) | DDB1CRBNL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617867-B2 | Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| US-12377163-B2 | Anti-B7H3 antibody-exatecan analog conjugate and medicinal use thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD (CN) | 2025-08-05 | — | — | US | disclosed |
| EP-4549438-A1 | FIVE-MEMBERED AND SIX-MEMBERED NITROGEN-CONTAINING COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | Hangzhou Synrx Therapeutics Biomedical Technology Co., Ltd. (CN) | 2025-05-07 | — | — | EP | disclosed |
| CN-119591621-A | Novel ecteinascidin derivatives, preparation method and application thereof, antibody drug conjugate and application thereof | 泰诚思(上海)生物医药有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-115103691-B | Pharmaceutical composition containing antibody drug conjugate and application thereof | 苏州盛迪亚生物医药有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-119185572-A | Ligand-drug conjugate of irinotecan analogue, preparation method and application thereof | 江苏恒瑞医药股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-118903456-A | Ligand-drug conjugate of irinotecan analogue, preparation method and application thereof | 江苏恒瑞医药股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118892553-A | Esatitecan analogue, ligand-drug conjugate thereof and application thereof | 浙江大学 | 2024-11-05 | — | — | CN | disclosed |
| CN-118873679-A | Anti-TROP-2 antibody-irinotecan analogue conjugate and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-118806924-A | Ligand-drug conjugate of irinotecan analogue, preparation method and application thereof | 江苏恒瑞医药股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-7342014-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617867-B2 | Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof | EGFR, CCKAR, MET | DDB1 3361/4885CRBN 618/4885ALDH1A1 2533/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | DDB1 430/4885CRBN 4226/4885ALDH1A1 3430/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | DDB1 142/4885CRBN 4367/4885ALDH1A1 3319/4885 |
| US-20080015215-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | DDB1 142/4885CRBN 4367/4885ALDH1A1 3319/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | DDB1 142/4885CRBN 4367/4885ALDH1A1 3319/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | DDB1 142/4885CRBN 4367/4885ALDH1A1 3319/4885 |
| US-12377163-B2 | Anti-B7H3 antibody-exatecan analog conjugate and medicinal use thereof | CD274, PDCD1LG2, SUV39H2 | DDB1 4592/4885CRBN 2767/4885ALDH1A1 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.